DNA-level biomarker can predict overall survival for rare brain tumors

(Ohio State University Wexner Medical Center) MGMT promoter methylation status -- information gathered at a DNA-level -- can help predict overall survival for patients with a rare form of brain cancer known as anaplastic astrocytoma, according to a new analysis from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news